Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DynaGen licenses breast biopsy technology:

This article was originally published in Clinica

Executive Summary

US company DynaGen has licensed BioLoc's technology for improving breast surgical biopsy procedures. The company says the technique overcomes problems with core needle biopsy procedures by guiding instruments directly to the suspected tissue lesion. Some eight million women in the US undergo breast screening annually. Of these, around 750,000 have surgical biopsies at a cost of $1,500 to $5,000 per treatment. The breast biopsy market is estimated at around $1,000 million.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT089791

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel